Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

NCT01121588 ·Status: TERMINATED ·Phase: PHASE1

Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer

NCT03647111 ·Status: RECRUITING

Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC

NCT02824094 ·Status: NO_LONGER_AVAILABLE

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

NCT03052608 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

NCT05297890 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer

NCT03646994 ·Status: RECRUITING

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

NCT06092086 ·Status: RECRUITING ·Phase: PHASE2

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

NCT04009317 ·Status: UNKNOWN ·Phase: PHASE3

Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

NCT03972189 ·Status: UNKNOWN ·Phase: PHASE2

Therapeutic Effect of Crizotinib for Rearrangement-negative, High Phosphorylated ALK Patients

NCT05792644 ·Status: COMPLETED ·Phase: NA

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

NCT06564324 ·Status: RECRUITING ·Phase: PHASE3

A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

NCT03909971 ·Status: COMPLETED ·Phase: PHASE2

Crizotinib Continuation Clinical Study

NCT05160922 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)

NCT01597258 ·Status: COMPLETED

A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)

NCT05721950 ·Status: ACTIVE_NOT_RECRUITING

Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC

NCT06934590 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT02838420 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation

NCT02961270 ·Status: UNKNOWN ·Phase: PHASE2

X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

NCT03215693 ·Status: UNKNOWN ·Phase: PHASE2

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

NCT06862869 ·Status: RECRUITING

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

NCT03123484 ·Status: UNKNOWN ·Phase: PHASE2

Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

NCT04211922 ·Status: TERMINATED ·Phase: PHASE2

Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

NCT03410108 ·Status: COMPLETED ·Phase: PHASE2

A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

NCT06254599 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

NCT04111705 ·Status: COMPLETED ·Phase: PHASE2